Helium charged-particle radiotherapy of locally advanced carcinoma of the esophagus, stomach, and biliary tract.
Sixty-five patients with squamous carcinoma of the esophagus (32 patients), carcinoma of the stomach (18 patients) and carcinoma of the biliary tract (15 patients) received from 6000 to 7000 equivalent rad (60-70 Gray-equivalents) of helium radiotherapy at 2.0 GyE per fraction, four fractions per day, using multiportal, spread-out Bragg peak therapy. All patients had locally advanced disease without evidence of distant metastases. Partial compensation for tissue inhomogeneities was accomplished. Although palliation of symptoms and regression of tumor was commonly seen, local failure occurred in most patients (77%). The median survival was 8 months. It does not appear that an increase in tumor dose relative to normal tissues can be achieved that would be high enough to increase locoregional control rates over historical control rates with low-LET irradiation. Further studies will be carried out with heavier particles such as neon or silicon in hopes of achieving greater biological effect on these difficult-to-control tumors.
D000230:Adenocarcinoma / Q000532:radiotherapy*; D001661:Biliary Tract Neoplasms / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D004938:Esophageal Neoplasms / Q000532:radiotherapy*; D005069:Evaluation Studies as Topic; D006371:Helium / Q000627:therapeutic use*; D006801:Humans; D011836:Radiation Tolerance; D013274:Stomach Neoplasms / Q000532:radiotherapy*
D006371:Helium